

+

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/214,881
Filing Date	June 7, 1999
First Named Inventor	Ozaki et al.
Group Art Unit	1644
Examiner Name	P. Nolan
Attorney Docket Number	068383.0104

Sheet	1	of	1
-------	---	----	---

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Pat Linn

Dated
Considered

6/29/04

HOU03:734562.1*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**



Form PTO-1449 (modified)

Atty. Docket No.
13240.0004.NPUS00Serial No.
09/214,881

List of Patents and Publications for Applicant's

Applicant
Ozaki et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
June 7, 1999Group:
1644U.S. Patent Documents
N/AForeign Patent Documents
N/AOther Art
See Page 1RECEIVED
DEC 10 2003
TECH CENTER 1800/2900

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	European Examination Report; August 28, 2003
PN	C2	"Anti-Neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis; anti-cathepsin G and a novel antibody correlate with a refractory type;" J. Sobajima, S. Ozaki, T. Okazaki, F. Osakada, S. Sumita, K. Mori & K. Nakao; 1996 Blackwell Science Ltd, Clinical and Experimental Immunology; pp. 120-124
PN	C3	"Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis;" Wolfgang L. Gross, Elena Csernok and Udo Helmchen; 1995 APMIS 103, pp. 81-97
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	C18	
	C19	
	C20	

EXAMINER: *Patricia J. Nolan*DATE CONSIDERED: *6/29/04*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)